4 completed, 1 terminated. 4 Phase 2, 1 Early Phase 1, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow pexacerfont: new trials by email Literature Review of pexacerfont trials Research Report on pexacerfont
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pexacerfont for Stress-induced Food Craving Pexacerfont - Daily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, Followed, Placebo | Early Phase 1 | Terminated | National Institute on Drug Abuse (NIDA) | 31 | 2012-06-01 | 2016-08-18 |
| Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^ Pexacerfont, Placebo - Alcohol-Related Disorders, Alcohol Dependence | Phase 2 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 70 | 2010-10-01 | 2016-02-02 |
| Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder pexacerfont, escitalopram, placebo - Generalized Anxiety Disorder | Phase 2 / Phase 3 | Completed | Bristol-Myers Squibb | 260 | 2007-07-01 | 2015-10-12 |
| A Study of BMS-562086 in Patients With Irritable Bowel Syndrome Placebo, BMS-562086 - Irritable Bowel Syndrome | Phase 2 | Completed | Bristol-Myers Squibb | 39 | 2006-12-01 | 2008-09-26 |
| Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder Pexacerfont, Escitalopram, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 271 | 2005-11-01 | 2010-03-02 |
Alcohol-Related Disorders (1) · Alcoholism (1) · Anxiety Disorders (1) · Behavior, Addictive (1) · Depressive Disorder, Major (1) · Feeding Behavior (1) · Generalized Anxiety Disorder (1) · Irritable Bowel Syndrome (1)
Bristol-Myers Squibb (3) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · National Institute on Drug Abuse (NIDA) (1)
United States (5)
David H Epstein, Ph.D. (1) · Markus A Heilig, M.D. (1)